Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC
| dc.contributor.author | Penrod, J. | |
| dc.contributor.author | Dang, T. | |
| dc.contributor.author | Yin, L. | |
| dc.contributor.author | Lopes, G. | |
| dc.contributor.author | Turna, H. Z. | |
| dc.contributor.author | Mok, T. S. K. | |
| dc.contributor.author | Wu, Y-L. | |
| dc.contributor.author | Kudaba, I. | |
| dc.contributor.author | Kowalski, D. M. | |
| dc.contributor.author | Cho, B. C. | |
| dc.contributor.author | de Castro, G. | |
| dc.contributor.author | Srimuninnimit, V. | |
| dc.contributor.author | Laktionov, K. K. | |
| dc.contributor.author | Bondarenko, I. | |
| dc.contributor.author | Kubota, K. | |
| dc.contributor.author | Caglevic, C. | |
| dc.contributor.author | Karaszewska, B. | |
| dc.date.accessioned | 2021-03-03T09:45:00Z | |
| dc.date.available | 2021-03-03T09:45:00Z | |
| dc.identifier.citation | Mok T. S. K. , Wu Y., Kudaba I., Kowalski D. M. , Cho B. C. , Turna H. Z. , de Castro G., Srimuninnimit V., Laktionov K. K. , Bondarenko I., et al., "Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC", European Lung Cancer Congress (ELCC), Geneva, İsviçre, 10 - 13 Nisan 2019, cilt.30, ss.38 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_1eaee2be-5ca0-42db-8c5a-1771c72c48be | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/25773 | |
| dc.language.iso | eng | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Onkoloji | |
| dc.subject | ONKOLOJİ | |
| dc.subject | Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.title | Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC | |
| dc.type | Bildiri | |
| dc.contributor.department | Chinese University of Hong Kong , , | |
| dc.identifier.volume | 30 | |
| dc.contributor.firstauthorID | 155998 |
Bu öğenin dosyaları:
| Dosyalar | Boyut | Biçim | Göster |
|---|---|---|---|
|
Bu öğe ile ilişkili dosya yok. |
|||
Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.
-
Bildiri [64839]